|
| << previous | next >> |
Journal description
All volumes of the corresponding journal
All issues of the corresponding volume
All articles of the corresponding issues
Details for article 30 of 39 found articles
| Title: |
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study |
| Author: |
Shao, Guoliang Bai, Yuxian Yuan, Xianglin Chen, Xiaomin Gu, Shanzhi Gu, Kangsheng Hu, Chunhong Liang, Houjie Guo, Yabing Wang, Jufeng Yen, Chia-Jui Lee, Victor Ho-Fun Wang, Chunxiao Widau, Ryan C. Zhang, Wanli Liu, Junjun Zhang, Qiang Qin, Shukui |
| Appeared in: |
EClinicalMedicine |
| Paging: | Volume 54 () nr. C pages p. |
| Year: |
2022 |
| Contents: | |
| Publisher: |
Eli Lilly and Company |
| Source file: |
Elektronische Wetenschappelijke Tijdschriften |
Details for article 30 of 39 found articles
| << previous | next >> |